Displaying 81 - 100 of 1549
FTC Staff Comment to Department of Labor on Proposed Amendments to Regulations Implementing the Mental Health Parity and Addiction Equity Act
FTC Issues Policy Statement on Brand Pharmaceutical Manufacturers’ Improper Listing of Patents in the Food and Drug Administration’s ‘Orange Book’
Amgen Inc. and Horizon Therapeutics plc; Analysis of Agreement Containing Consent Order To Aid Public Comment
American Screening, LLC
The Â鶹´«Ã½ Trade Commission filed suit against American Screening for failing to deliver on promises that it could quickly ship products like face masks, sanitizer, and other personal protective equipment (PPE) related to the coronavirus pandemic.
The lawsuits allege that the companies violated the FTC’s Mail, Internet and Telephone Order Rule (Mail Order Rule), which requires that companies notify consumers of shipping delays in a timely manner and give consumers the chance to cancel orders and receive prompt refunds.
Agency Information Collection Activities; Proposed Collection; Comment Request; Extension (Contact Lens Rule)
Surescripts LLC
The FTC sued the health information company Surescripts, alleging that the company employed illegal vertical and horizontal restraints in order to maintain its monopolies over two electronic prescribing, or “e-prescribing,†markets: routing and eligibility. According to the complaint, Surescripts monopolized two separate markets for e-prescription services: The market for routing e-prescriptions, which uses technology that enables health care providers to send electronic prescriptions directly to pharmacies; and the market for determining eligibility, a separate service that enables health care providers to electronically determine patients’ eligibility for prescription coverage through access to insurance coverage and benefits information, usually through a pharmacy benefit manager.The FTC alleges that Surescripts intentionally set out to keep e-prescription routing and eligibility customers on both sides of each market from using additional platforms (a practice known as multihoming) using anticompetitive exclusivity agreements, threats, and other exclusionary tactics. Among other things, the FTC alleges that Surescripts took steps to increase the costs of routing and eligibility multihoming through loyalty and exclusivity contracts.
In July 2023, the FTC filed a proposed order that would resolve the Commission’s charges. The proposed order prohibits Surescripts from engaging in exclusionary conduct and executing or enforcing non-compete agreements with current and former employees. The proposed order also goes beyond routing and eligibility, extending the same prohibitions to Surescripts’ medication history services and the company’s on-demand formulary services.
Statement Regarding Termination of CooperCompanies’ Attempted Acquisition of Cook Medical’s Reproductive Health Business
FTC Reaches Proposed Settlement with Surescripts in Illegal Monopolization Case
FTC Votes to Issue Statement Withdrawing Prior Pharmacy Benefit Manager Advocacy
FTC Sues to Block IQVIA’s Acquisition of Propel Media to Prevent Increased Concentration in Health Care Programmatic Advertising
Â鶹´«Ã½ Trade Commission Withdraws Health Care Â鶹´«Ã½ Policy Statements
FTC Announces Tentative Agenda for July 20 Open Commission Meeting
Easy Healthcare Corporation, U.S. v.
The FTC reached a settlement with the developer of the fertility app Premom over allegations it deceived users by sharing their sensitive personal information with third parties, including two China-based firms, disclosed users’ sensitive health data to AppsFlyer and Google, and failed to notify consumers of these unauthorized disclosures in violation of the Health Breach Notification Rule (HBNR).
FTC Files Amicus Brief in Bystolic Antitrust Litigation Supporting Competition in the Hypertension Drug Market
FTC Policy Director Issues Statement Commending Maine’s Repeal of Certificate of Public Advantage Law
16 CFR Part 318: Health Breach Notification Rule (NPRM)
Displaying 81 - 100 of 1549